obstructive airway disease


Also found in: Acronyms.

obstructive airway disease

[əbstruk′tiv]
any respiratory disease characterized by air trapping caused by either decreased airway diameter or increased airway secretions, or both. It includes chronic bronchitis and emphysema. See also chronic obstructive pulmonary disease, cystic fibrosis.

obstructive airway disease

A general term for any condition in which the movement of normal quantities of oxygen from the atmosphere to the blood is prejudiced. The term ‘chronic obstructive airway disease’ (COAD) is usually limited to chronic BRONCHITIS and EMPHYSEMA.
References in periodicals archive ?
Moreover, anatomic factors such as chronic obstructive airway disease (which might have weakened the trachea) and tumor infiltration of peritracheal tissue might have also aggravated the tracheal injury.
ProAir[R] HFA was approved by the FDA in October 2004 for treatment or prevention of bronchospasm with reversible obstructive airway disease in adults and children 12 years of age and older.
Reversible obstructive airway disease includes respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD).
According to the firm, the albuterol multi-dose dry-powder inhaler (MDPI) is indicated to treat or prevent bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.
Food and Drug Administration (FDA) for XOPENEX HFA(TM) (levalbuterol tartrate HFA) Inhalation Aerosol, a hydrofluoroalkane (HFA) metered-dose inhaler (MDI) for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease, such as asthma and chronic obstructive pulmonary disease (COPD).
XOPENEX HFA is a short-acting beta-agonist indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.
XOPENEX HFA is a single-isomer short-acting bronchodilator that is indicated for the treatment or prevention of bronchospasm in patients 4 years and older with reversible obstructive airway disease.
XOPENEX brand levalbuterol HCl inhalation solution is indicated for the treatment or prevention of bronchospasm in patients 6 years and older with reversible obstructive airway disease, such as asthma.
On March 11, 2005, the FDA approved Sepracor's New Drug Application (NDA) for XOPENEX HFA(TM) (levalbuterol tartrate) Inhalation Aerosol, a hydrofluoroalkane (HFA) MDI for the treatment or prevention of bronchospasm in adults, adolescents and children 4 years of age and older with reversible obstructive airway disease.
Nasdaq: SEPR) today announced that (R,R)-formoterol inhalation solution has advanced into Phase III studies for the treatment of bronchospasm in patients with obstructive airway disease.
Sepracor currently has approximately 200 sales representatives that call on pediatricians, pulmonologists, allergists and primary care physicians for XOPENEX inhalation solution, which is indicated for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, such as asthma.